Clinical evolution of acute bronchitis in Colombian children between 2 and 14 years treated with Hedera helix EA575 syrup

Aim: To describe the experience of use and clinical evolution of patients with acute bronchitis treated with Hedera helix EA575 syrup for seven days. Methods: A descriptive observational study based on clinical records, which included patients between 2-14 years old with acute bronchitis prescribed by their doctor Hedera helix EA575 syrup. Sociodemographic data and the time of evolution of the cough were taken from the baseline consultation. Treatment-related variables, BSS-Pediatric Scale, visual analogue cough scale, and verbal descriptive cough score were taken from the follow-up. The satisfaction with the treatment and its success were evaluated after 14 days. Results: 80 patients between 2 and 12 years old were included. The median number of cough days was eight days. After 7 and 14 days of treatment, 50% and 76% had resolved the cough, respectively. On day 14, coughing was frequent without interfering with activities in 1 patient. The BSS-pediatric score decreased at each follow-up. Median day-and-night cough VAS was zero for day 14. Awakenings due to coughing decreased from 3 at baseline to 0 per week. 98.75% of the patients were satisfied with the treatment, and none presented adverse events. Conclusions: After seven days of treatment, half of the patients had resolved cough and night awakenings; it is suggested that treatment with Hedera helix EA575 could be beneficial and of low risk.